LSB Company Report

Analyst Coverage

Research analysts covering LSB.

Recent press releases and 8-K filings for LSB.

LakeShore Biopharma Transitions to OTC Market Following Nasdaq Delisting

LSB

Delisting/Listing Issues

LakeShore Biopharma's ordinary shares and warrants were suspended from trading on The Nasdaq Capital Market effective September 22, 2025.
The company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market under the symbols "LSBCF" and "LSBWF" on September 22, 2025.
The delisting from Nasdaq was due to non-compliance with the minimum bid price requirement and ineligibility for a compliance period following a prior reverse stock split.
LakeShore Biopharma will remain a reporting company with the U.S. Securities and Exchange Commission despite the transition to the OTC Market.

Sep 22, 2025, 12:10 PM

LakeShore Biopharma Shares Transition to OTC Market Following Nasdaq Delisting

LSB

Delisting/Listing Issues

LakeShore Biopharma's (LSB) ordinary shares and warrants were suspended from trading on The Nasdaq Capital Market and began trading on the OTC Pink Open Market under the symbols "LSBCF" and "LSBWF" on September 22, 2025.
The delisting followed a Nasdaq determination on September 11, 2025, due to the company's non-compliance with the minimum bid price requirement and ineligibility for a compliance period after a prior reverse stock split.
The transition to the OTC Market does not change LakeShore Biopharma's business operations, and the company remains a reporting entity with the U.S. Securities and Exchange Commission.

Sep 22, 2025, 12:00 PM

LakeShore Biopharma Receives Nasdaq Delisting Determination

LSB

Delisting/Listing Issues

LakeShore Biopharma (LSB) received a delisting determination letter from Nasdaq on September 11, 2025, for non-compliance with the Bid Price Rule, as its closing bid price was below $1.00 per share for 30 consecutive business days.
The company is ineligible for the standard 180-day compliance period due to a 10-for-1 reverse stock split effected on October 1, 2024.
Nasdaq has determined to delist LSB's securities, with trading suspension scheduled for the opening of business on September 22, 2025, unless the company requests an appeal.
LSB has until September 18, 2025, to request a hearing before a Nasdaq Hearings Panel, but there is no assurance that an appeal would be successful or that the company will regain compliance.

Sep 12, 2025, 1:05 PM

Get instant answers from SEC filings, earnings calls & more